Satish Garg, MD
Endocrinology, Diabetes & Metabolism · Aurora, CONPI 1447264767
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.0%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 22.8%. Reporting peaked in 2019 at $120,181 and has fallen 56.6% since, to $52,112 in 2025. Among endocrinology, diabetes & metabolism clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 299 payments — averaging $1159.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Roche Diabetes Care GmbH$79K
- Medtronic$72K
- Novo Nordisk$53K
- Novo Nordisk AS$23K
- Dexcom, Inc.$21K
- Eli Lilly$18K
- plus $81K from 20 others
Across 211 payments — averaging $39,621 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dexcom, Inc.$4.5M
- Medtronic$2.9M
- Eli Lilly$888K
- Novo Nordisk AS$13K
- Novo Nordisk$10K
- Sanofi-aventis U.S. LLC$2K
What the payments were for
- Consulting fees$193,99356%
- Speaking & faculty fees$53,67315%
- Travel & lodging$90,00126%
- Food & beverage$8,9183%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Roche Diabetes Care GmbH | 28 | $79,076 |
| Medtronic(2 entities) | 109 | $71,763 |
| Novo Nordisk | 22 | $53,397 |
| Novo Nordisk AS | 13 | $22,907 |
| Dexcom, Inc. | 10 | $20,929 |
| Eli Lilly | 28 | $17,718 |
| Lifescan, Inc. | 13 | $15,936 |
| Boehringer Ingelheim | 10 | $11,604 |
| Zealand Pharma US, Inc. | 10 | $9,299 |
| Embecta Corp. | 2 | $7,194 |
| Convatec Inc. | 5 | $6,960 |
| Astrazeneca UK Limited | 3 | $4,647 |
| AstraZeneca | 1 | $4,000 |
| Zealand Pharma A/s | 1 | $3,750 |
| Lexicon Pharmaceuticals, Inc. | 7 | $3,737 |
| Senseonics, Incorporated | 1 | $3,500 |
| F. Hoffmann-la Roche AG | 3 | $2,500 |
| Vertex | 7 | $2,033 |
| Sanofi-aventis U.S. LLC | 5 | $1,412 |
| Corcept Therapeutics | 1 | $1,400 |
| Mannkind Corporation | 3 | $1,311 |
| Abbott | 11 | $685 |
| Tandem Diabetes Care, Inc. | 2 | $550 |
| Roche Diabetes Care, Inc. | 2 | $193 |
| Roche Diagnostics Corporation | 1 | $67 |
| Genentech, Inc. | 1 | $48 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Accu-Chek Inform II Instrument with RF card$53,131
- DC ACCU-CHEK Diabetes Management Solutions, Cables, Software, Kits and Accessori$23,313
- JARDIANCE$11,400
- DEXCOM G7 GSS (161)$10,439
- DEXCOM G6 CGM SYSTEM$9,988
- ZEGALOGUE$9,299
- Minimed 670G System$8,689
- MINIMED 780G$5,408
- FARXIGA$4,585
- Dasiglucagon$3,750
- Eversense$3,500
- AQUACEL AG$3,145
- AQUACEL Ag Extra$3,125
- Accu-Chek Instruments$2,220
- OneTouch$1,920
- Korlym$1,400
- SOTAGLIFLOZIN$1,364
- AFREZZA$1,275
- MINIMED 770G$1,083
- AQUACEL Ag Advantage Surgical$690
How this compares
$346,616 in reported general payments places this provider in the 95th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
See all endocrinology, diabetes & metabolism providers in Colorado →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 29 | $31,064 |
| OzempicSemaglutide | 15 | $30,422 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $19,645 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $16,354 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $11,264 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 12 | $9,336 |
| Humalog Kwikpen U-100Insulin Lispro | 14 | $7,673 |
| Insulin Degludec Pen (U-200)Insulin Degludec | 12 | $2,234 |
| Levothyroxine Sodium | 44 | $551 |
| Losartan Potassium | 22 | $373 |
| Simvastatin | 22 | $338 |
| Allopurinol | 33 | $198 |
| Amlodipine Besylate | 16 | $149 |
| Atorvastatin Calcium | 14 | $124 |
| Metformin Hcl | 16 | $55 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $53,397 | $30,42215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
Other endocrinology, diabetes & metabolism in Aurora
- Viralkumar ShahAurora$256K
- Neda RasouliAurora$188K
- Halis AkturkAurora$109K
- Robert EckelAurora$66K
- Marc Andre CornierAurora$62K
- Jane ReuschAurora$59K
- James FalkoAurora$45K
- Aaron MichelsAurora$37K
- Margaret WiermanAurora$36K
- Peter GottliebAurora$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.